TriSalus Life Sciences

TLSI on Nasdaq. Surgical & medical instruments & apparatus. Market value $150m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-16.5%low

For every $100 of what the whole company costs, it produced $-16.49 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$2.43 a share, 10% above its 1-year low

Over the past year the price has ranged from $2.20 to $7.95.

Pays no dividend

Price from Friday’s close (13 November).

Five years of cash, in billions

n/a
-0.0
-0.1
-0.0
-0.0
-0.0
2021202220232024202512 monthsto Sep '26
Revenue
n/a$12m$19m$29m$45m
Operating margin
n/a-293.9%-294.3%-122.9%-59.7%
Debt to equity
n/an/an/an/an/a
Shares outstanding
n/a0.03bn0.03bn0.05bn0.06bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsStrong, 53.8% a year

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $13 million last quarter, up 11% on a year ago.
  • A loss of $9 million, compared with a loss of $11 million a year ago.
  • It loses 63 cents on each $1 of sales, compared with 78 cents a year earlier.
  • Over the past 12 months it spent $25 million more cash than it brought in, compared with $22 million a year earlier.
  • 36% more shares than a year ago. Each share owns a bit less of the company.
  • It has $9 million more cash than debt. A year ago debt was $10 million more than cash.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$8m
March 2025$9m
June 2025$11m
September 2025$12m
December 2025$13m
March 2026$9m
June 2026$11m
September 2026$13m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$10m
March 2025-$10m
June 2025-$8m
September 2025-$11m
December 2025-$10m
March 2026$2m
June 2026-$9m
September 2026-$9m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
9 February 2027

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 79 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • Frankenius Equity AB
    Passive investor
    at least 14.0%−6.5 pts
    (filed with 1 related holder)
    Since 31 July 2025
    What they said

    Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3…

    Read the filing
  • at least 12.0%+1.3 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • Mats Wahlstrom
    at least 6.0%−3.0 pts
    (filed with 2 related holders)
    Since 31 July 2025
    What they said

    Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3…

    Read the filing
  • Utmost Group PLC
    Passive investor
    5.7%−1.1 pts
    Since 31 March 2026
  • James J. Pallotta
    Passive investor
    5.2%
    Since 15 May 2026
  • at least 4.1%−1.2 pts
    (filed with 2 related holders)
    Since 30 September 2025
  • HW Investment Partners, LLC
    Insider or founder
    Sold down below 5%
    Since 17 December 2024
  • Lombard International Assurance S.A.
    Passive investor
    Sold down below 5%
    Since 30 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 6 insiders bought $4m of shares on the open market. 5 sold $141,244.

Cluster buy3 insiders bought within 30 days (12 November 2026 to 18 November 2026).
  • Szela Mary T
    CEO and President, Director
    Bought
    Date
    18 November 2026
    Shares
    34,328
    Price
    $2.59
    Value
    $88,910
  • Szela Mary T
    CEO and President, Director
    Bought
    Date
    17 November 2026
    Shares
    30,864
    Price
    $2.31
    Value
    $71,296
  • Gordon Gary B.
    Director
    Bought
    Date
    17 November 2026
    Shares
    10,000
    Price
    $2.20
    Value
    $22,000
  • Marshak Richard
    Chief Commercial Officer
    Sold
    Date
    16 November 2026
    Shares
    544
    Price
    $2.43
    Value
    $1,322
  • Wahlstrom Mats
    Director
    Bought
    Date
    12 November 2026
    Shares
    50,000
    Price
    $2.24
    Value
    $112,000
  • Cox Bryan F.
    Chief of Research
    Sold
    Date
    5 October 2026
    Shares
    296
    Price
    $4.39
    Value
    $1,299
  • Marshak Richard
    Chief Commercial Officer
    Sold
    Date
    5 October 2026
    Shares
    325
    Price
    $4.39
    Value
    $1,427
  • Stevens Jennifer
    Chief Regulatory Officer
    Sold
    Date
    5 October 2026
    Shares
    316
    Price
    $4.39
    Value
    $1,387
  • Marshak Richard
    Chief Commercial Officer
    Sold
    Date
    15 May 2026
    Shares
    543
    Price
    $2.67
    Value
    $1,450
  • Wahlstrom Mats
    Director
    Bought
    Date
    15 May 2026
    Shares
    60,000
    Price
    $2.53
    Value
    $151,800

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in TriSalus Life Sciences’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 7 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based upon that evaluation, our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have concluded that our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting previously identified, which continues to exist as of September 30, 2026, as discussed below.”
    Show the full paragraph
    Disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) are designed only to provide reasonable assurance that information to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial and accounting officer), of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have concluded that our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting previously identified, which continues to exist as of September 30, 2026, as discussed below. Management’s assessment of the effectiveness of our disclosure controls and procedures is expressed at a level of reasonable assurance because management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.

    From the 10-Q filed 10 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

Insiders have been buying together. The deep dive checks whether they know something the price doesn't.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.